Angel Biotechnology Holdings plc, the biopharmaceutical contract manufacturer, is announced pre-GMP process development programme with Angport Limited. The contract is the first to be signed under the EPhaG relationship announced in May 2008.

Under the contract, Angel will develop and scale up GMP compliant processes for Angportss DNAase projects. Following successful completion of this programme of work, Angel and Angport intend to engage in further contracts for the GMP manufacture of material for clinical trials and if successful, the commercial supply of the product, yielding royalties to Angel. The development project will be carried out over a period of six months at Angels facilities in Edinburgh.

Commenting on the contract, Gordon Sherriff, Angels chief operating officer said: We are pleased to have been selected by Angport to be its manufacturing partner. Angels capability to manufacture Licensed material under our Manufacturers and Importers Authorisation (MIA) from the Medicines and Healthcare Products Regulatory Agency (MHRA) has been key in enabling us to secure this contract. The project is important to Angel, fitting well with our core capabilities and providing further evidence of our ability to attract such business. This project also fits well with Angels strategy of long term partnering with clients.

Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing to support biotechnology and pharmaceutical companies worldwide.